Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine
Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 12627
- GSK Investigational Site
-
Berlin, Alemanha, 13507
- GSK Investigational Site
-
Berlin, Alemanha, 13355
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Ettenheim, Baden-Wuerttemberg, Alemanha, 77955
- GSK Investigational Site
-
Kehl, Baden-Wuerttemberg, Alemanha, 77694
- GSK Investigational Site
-
Oberkirch, Baden-Wuerttemberg, Alemanha, 77704
- GSK Investigational Site
-
Offenburg, Baden-Wuerttemberg, Alemanha, 77654
- GSK Investigational Site
-
-
Bayern
-
Cham, Bayern, Alemanha, 93413
- GSK Investigational Site
-
Kaufering, Bayern, Alemanha, 86916
- GSK Investigational Site
-
Landshut, Bayern, Alemanha, 84032
- GSK Investigational Site
-
Muenchen, Bayern, Alemanha, 80939
- GSK Investigational Site
-
Olching, Bayern, Alemanha, 82140
- GSK Investigational Site
-
Weilheim, Bayern, Alemanha, 82362
- GSK Investigational Site
-
-
Hessen
-
Eschwege, Hessen, Alemanha, 37269
- GSK Investigational Site
-
Koenigstein, Hessen, Alemanha, 61462
- GSK Investigational Site
-
-
Niedersachsen
-
Salzgitter, Niedersachsen, Alemanha, 38226
- GSK Investigational Site
-
Wolfenbuettel, Niedersachsen, Alemanha, 38302
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Erkrath, Nordrhein-Westfalen, Alemanha, 40699
- GSK Investigational Site
-
Goch, Nordrhein-Westfalen, Alemanha, 47574
- GSK Investigational Site
-
Guetersloh, Nordrhein-Westfalen, Alemanha, 33332
- GSK Investigational Site
-
Heiligenhaus, Nordrhein-Westfalen, Alemanha, 42579
- GSK Investigational Site
-
Kleve-Materborn, Nordrhein-Westfalen, Alemanha, 47533
- GSK Investigational Site
-
Krefeld, Nordrhein-Westfalen, Alemanha, 47798
- GSK Investigational Site
-
Loehne, Nordrhein-Westfalen, Alemanha, 32584
- GSK Investigational Site
-
Muenster, Nordrhein-Westfalen, Alemanha, 48159
- GSK Investigational Site
-
Willich, Nordrhein-Westfalen, Alemanha, 47877
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Bad Kreuznach, Rheinland-Pfalz, Alemanha, 55543
- GSK Investigational Site
-
Frankenthal, Rheinland-Pfalz, Alemanha, 67227
- GSK Investigational Site
-
Mainz, Rheinland-Pfalz, Alemanha, 55131
- GSK Investigational Site
-
Trier, Rheinland-Pfalz, Alemanha, 54294
- GSK Investigational Site
-
Worms, Rheinland-Pfalz, Alemanha, 67547
- GSK Investigational Site
-
Worms, Rheinland-Pfalz, Alemanha, 67549
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Alemanha, 01307
- GSK Investigational Site
-
Dresden, Sachsen, Alemanha, 01169
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Brunsbuettel, Schleswig-Holstein, Alemanha, 25541
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Alemanha, 24937
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Alemanha, 24939
- GSK Investigational Site
-
Flensburg, Schleswig-Holstein, Alemanha, 24943
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- A male or female subject who received a booster vaccination with dTpa-IPV or dTpa + IPV in study 711866/001.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Females of childbearing potential at the time of study entry must have a negative pregnancy test prior to administration of the dose of vaccine and are required to be abstinent or to use adequate contraceptive precautions for one month prior to vaccination. Subjects are required to agree to continue such precautions for two months after vaccination.
- Written informed consent obtained from both parents/ guardians of the subject; assent from the subject himself/herself should also be requested whenever possible.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs within six months prior to the booster dose.
- Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- Previous booster vaccination against tetanus, diphtheria, pertussis, or poliomyelitis since the booster dose received in study 711866/001.
- History of diphtheria, tetanus, pertussis, or poliomyelitis diseases.
- Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Administration of immunoglobulin and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
- Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
- Occurrence of any of the following adverse events (AEs) after a previous administration of a DTP vaccine: hypersensitivity reaction to any component of the vaccine, encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine, fever ≥ 40°C within 48 hours of vaccination not due to another identifiable cause, collapse or shock-like state within 48 hours of vaccination
- Persistent, severe, inconsolable screaming or crying lasting >3 hours occurring within 48 hours of receipt of a previous dose of DTP vaccine convulsions with or without fever, occurring within 3 days of vaccination.
- Acute disease at the time of enrolment.
- Pregnant or lactating female.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: BOOSTRIX-POLIO GROUP
Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
|
A single booster dose of dTpa-IPV vaccine will be administered to all subjects.
IM administration in the deltoid muscle of the non-dominant arm.
|
|
Experimental: BOOSTRIX + IPV MÉRIEUX GROUP
Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
|
A single booster dose of dTpa-IPV vaccine will be administered to all subjects.
IM administration in the deltoid muscle of the non-dominant arm.
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Subjects With Any Grade 3 Solicited Local Symptoms
Prazo: During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Grade 3 Pain: Pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
|
During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de indivíduos com quaisquer sintomas locais solicitados
Prazo: Durante o período de acompanhamento de 4 dias (dias 0-3) após a vacinação de reforço
|
Os sintomas locais solicitados avaliados foram dor, vermelhidão e inchaço.
Qualquer = ocorrência do sintoma independentemente do grau de intensidade.
|
Durante o período de acompanhamento de 4 dias (dias 0-3) após a vacinação de reforço
|
|
Number of Subjects With Any Solicited General Symptoms
Prazo: During the 4-day (Days 0-3) follow-up period after booster vaccination
|
Assessed solicited general symptoms were fatigue, gastrointestinal, headache and temperature [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade and relationship to vaccination.
|
During the 4-day (Days 0-3) follow-up period after booster vaccination
|
|
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Toxoids
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Anti-D and anti-T antibody concnetration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL) and ≥ 1 IU/mL have been assessed by enzyme-linked immunosorbent assay (ELISA).
Pre-vaccination sera with ELISA concentrations < 0.1 IU/mL were tested for neutralising antibodies using a Vero-cell neutralisation assay with a 0.016 IU/mL cut-off.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Anti-D and Anti-T Antibody Concentrations
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 ELISA unit per milliliter (EL.U/ml).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibodies concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ the value of 8.
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Anti-Polio 1, 2 and 3 Antibody Titers
Prazo: Prior to (Month 0) and one month after (Month 1) booster vaccination
|
Antibody titers were presented as geometric mean titers (GMTs).
|
Prior to (Month 0) and one month after (Month 1) booster vaccination
|
|
Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN
Prazo: One month after booster vaccination (At Month 1)
|
Booster vaccine response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations < 5 EL.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations < 5 EL.U/mL).
|
One month after booster vaccination (At Month 1)
|
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Prazo: During the 31-day (Days 0-30) follow-up period after booster vaccination
|
AEs results are presented for all subjects.
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
During the 31-day (Days 0-30) follow-up period after booster vaccination
|
|
Number of Subjects With Serious Adverse Events (SAEs)
Prazo: During the entire booster period (Month 0 to Month 1)
|
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
During the entire booster period (Month 0 to Month 1)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Publicações Gerais
- Mertsola J et al. The safety of repeated administration of Boostrix™, a reduced-antigen-content dTpa booster. Abstract presented at Excellence In Paediatrics (EIP). Florence, Italy, 3-6 December 2009.
- Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. Hum Vaccin Immunother. 2012 Jul;8(7):866-72. doi: 10.4161/hv.20229. Epub 2012 Apr 9.
- Mertsola J et al. The safety of repeated administration of reduced-antigen-content dTpa boosters. Abstract presented at WSPID-6th World Congress. Buenos Aires, Argentina, 19-22 November 2009.
- Knuf M et al. The repeated administration of a reduced antigen content diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (dTpa-IPV; BoostrixTM IPV) in adolescents. Abstract presented at IDSA. Philadelphia, USA, 29 October- 1 November 2009.
- Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix IPV). Hum Vaccin. 2010 Jul;6(7):554-61. doi: 10.4161/hv.6.7.11760.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções do Trato Respiratório
- Doenças Respiratórias
- Doenças Neuromusculares
- Infecções do Sistema Nervoso Central
- Infecções por Bordetella
- Infecções por Bactérias Gram-negativas
- Infecções bacterianas
- Infecções Bacterianas e Micoses
- Infecções por Bactérias Gram-Positivas
- Infecções por Actinomycetales
- Infecções por Enterovírus
- Infecções por Picornaviridae
- Doenças da Medula Espinhal
- Infecções por Clostridium
- Infecções por Corynebacterium
- Mielite
- Coqueluche
- Tétano
- Difteria
- Poliomielite
Outros números de identificação do estudo
Outros números de identificação do estudo
- 110947
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Dados/documentos do estudo
-
Especificação do conjunto de dados
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Relatório de Estudo Clínico
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Consentimento Informado
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de dados de participantes individuais
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudo
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Plano de Análise Estatística
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Relato de Caso Anotado
Identificador de informação: 110947Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .